Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer

NCT05288166 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT05288166
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05288166 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 14, 2022
Completion date
October 31, 2027
Enrollment
925 (actual)
Sites
266

Conditions

As the registry lists them; a condition with its own page is linked.

abiraterone acetate, androgens, antineoplastic agents, antineoplastic agents, hormonal, cyclin-dependent kinase 4, cyclin-dependent kinase 6, cytochrome p-450, enzyme inhibitors, hormones, hormones, hormone substitutes, and hormone antagonists, neoplasm metastasis, physiological effects of drugs, prednisolone, prednisone, prostatic neoplasms, steroid synthesis inhibitors, urogenital neoplasms